The effects of a PCSK9-inhibitor on various lipid fractions
Gisette Reyes-Soffer (Columbia University Medical Center, New York City, NY, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
ISA2015 | Clinical Breakthroughs Gisette Reyes-Soffer shares the findings on the effect of PCSK9-inhibitor alirocumab on VLDL, IDL, LDL and apoB-metabolism in healthy volunteers.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: